ICAM2

Summary

ICAM2 (intercellular adhesion molecule 2, HGNC:5345) is a protein-coding gene on chromosome 17q23.3, encoding Intercellular adhesion molecule 2 (P13598). Cell adhesion molecule that functions as a receptor ligand of the signaling receptor ITGAL:ITGB2/LFA-1 (lymphocyte-function associated (LFA) molecule 1) ensuring leukocyte cell-cell adhesion on resting cells.

The protein encoded by this gene is a member of the intercellular adhesion molecule (ICAM) family. All ICAM proteins are type I transmembrane glycoproteins, contain 2-9 immunoglobulin-like C2-type domains, and bind to the leukocyte adhesion LFA-1 protein. This protein may play a role in lymphocyte recirculation by blocking LFA-1-dependent cell adhesion. It mediates adhesive interactions important for antigen-specific immune response, NK-cell mediated clearance, lymphocyte recirculation, and other cellular interactions important for immune response and surveillance. Several transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 3384 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 51 total
• MANE Select transcript: NM_001099789

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5345
Approved symbol	ICAM2
Name	intercellular adhesion molecule 2
Location	17q23.3
Locus type	gene with protein product
Status	Approved
Aliases	CD102
Ensembl gene	ENSG00000108622
Ensembl biotype	protein_coding
OMIM	146630
Entrez	3384

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 18 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000412356, ENST00000418105, ENST00000449662, ENST00000578313, ENST00000578379, ENST00000578892, ENST00000579687, ENST00000579788, ENST00000580011, ENST00000580389, ENST00000581417, ENST00000583186, ENST00000583366, ENST00000583684, ENST00000584084, ENST00000584403, ENST00000852957, ENST00000852958, ENST00000965113, ENST00000965114, ENST00000965115, ENST00000965116, ENST00000965117, ENST00000965118

RefSeq mRNA: 5 — MANE Select: NM_001099789 NM_000873, NM_001099786, NM_001099787, NM_001099788, NM_001099789

CCDS: CCDS11657

Canonical transcript exons

ENST00000579788 — 5 exons

Exon	Start	End
ENSE00002705765	64002595	64002925
ENSE00002716284	64020523	64020633
ENSE00003513662	64005107	64005373
ENSE00003562599	64006631	64006735
ENSE00003791597	64003644	64003964

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 98.32.

FANTOM5 (CAGE): breadth broad, TPM avg 24.1617 / max 475.8851, expressed in 813 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
167546	13.0791	706
167540	8.8452	396
167542	0.7963	184
167545	0.3841	128
167539	0.2982	99
167543	0.2944	92
167541	0.2858	128
167544	0.1786	94

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
spleen	UBERON:0002106	98.32	gold quality
granulocyte	CL:0000094	97.80	gold quality
vena cava	UBERON:0004087	97.35	gold quality
pericardium	UBERON:0002407	97.18	gold quality
apex of heart	UBERON:0002098	97.10	gold quality
right lung	UBERON:0002167	97.03	gold quality
upper lobe of lung	UBERON:0008948	96.58	gold quality
upper lobe of left lung	UBERON:0008952	96.54	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.45	gold quality
lower lobe of lung	UBERON:0008949	96.43	gold quality
omental fat pad	UBERON:0010414	96.42	gold quality
peritoneum	UBERON:0002358	96.39	gold quality
leukocyte	CL:0000738	95.71	gold quality
blood	UBERON:0000178	95.62	gold quality
mononuclear cell	CL:0000842	95.57	gold quality
monocyte	CL:0000576	95.56	gold quality
trabecular bone tissue	UBERON:0002483	95.55	gold quality
adipose tissue	UBERON:0001013	95.50	gold quality
lymph node	UBERON:0000029	95.29	gold quality
lung	UBERON:0002048	95.10	gold quality
subcutaneous adipose tissue	UBERON:0002190	95.05	gold quality
connective tissue	UBERON:0002384	94.98	gold quality
adult organism	UBERON:0007023	94.86	gold quality
superficial temporal artery	UBERON:0001614	94.74	gold quality
heart left ventricle	UBERON:0002084	94.53	gold quality
cardiac ventricle	UBERON:0002082	94.52	gold quality
placenta	UBERON:0001987	93.43	gold quality
periodontal ligament	UBERON:0008266	93.39	gold quality
heart right ventricle	UBERON:0002080	92.92	gold quality
visceral pleura	UBERON:0002401	92.62	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 14.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	753.12
E-MTAB-10287	yes	64.05
E-GEOD-135922	yes	48.51
E-HCAD-11	yes	47.89
E-HCAD-10	yes	44.20
E-HCAD-1	yes	39.60
E-MTAB-8410	yes	35.38
E-CURD-112	yes	34.09
E-MTAB-6701	yes	33.88
E-CURD-46	yes	26.25
E-MTAB-9388	yes	14.10
E-MTAB-6678	yes	12.32
E-MTAB-10137	yes	5.94
E-MTAB-6379	no	383.55
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ERG

miRNA regulators (miRDB)

6 targeting ICAM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3157-5P	97.41	67.61	998
HSA-MIR-214-5P	97.34	66.50	617
HSA-MIR-3944-3P	91.01	62.27	44
HSA-MIR-3181	88.42	63.57	25
HSA-MIR-4750-5P	80.79	59.79	18

Literature-anchored findings (GeneRIF, showing 28)

• Although ICAM-2 colocalizes with moesin and F-actin in microvilli of unstimulated endothelial cells, it is not involved in RhoA activation or cause stress fiber formation upon cross-linking. (PMID:12097408)
• soluble DC-SIGN bound to gp120-Fc more than 100- and 50-fold better than ICAM-2-Fc and ICAM-3-Fc, respectively. Binding sites are described. (PMID:14970226)
• N-Linked glycosylation regulate both conformation and immune related functions of ICAM receptors (PMID:15545280)
• The role of ICAM-2 has its recognition as potential therapeutic targets in human diseases. (PMID:15548573)
• mutation of the serine phosphorylation site leads to inability of Mac-1 to become activated to bind the cellular ligands ICAM-1 and ICAM-2. (PMID:16857989)
• persistently elevated, serum levels of ICAM-2 throughout the various phases and types of Hemorrhagic fever with renal syndrome (HFRS) may be associated with the hyperfunctioning of the cellular immune response. (PMID:16987074)
• pig and human ICAM-2 promoters exhibit many similarities (PMID:17059578)
• diminished ability of NK cells to kill HTLV-1-infected cells was the decreased ability of NK cells to adhere to HTLV-1-infected cells because of HTLV-1 p12(I)-mediated down-modulation of intercellular adhesion molecule 1 (ICAM-1) and ICAM-2. (PMID:17609265)
• The binding partner of DC-SIGN on endothelial cells is the glycan epitope Lewis(Y) (Le(Y)), expressed on ICAM-2. (PMID:18155766)
• Receptor tyrosine kinase EphA2 mediates thrombin-induced upregulation of ICAM-1 in endothelial cells in vitro. (PMID:18768213)
• ICAM-2 is expressed on the bronchial epithelium and, together with ICAM-1, has an essential function in the clearance of T cells from the lung (PMID:18842965)
• ICAM-2 mediates suppression of metastatic phenotype and the interaction of ICAM-2/alpha-actinin/actin represents the first complete membrane-linker protein-actin linkage to impact tumor cell motility in vitro and metastatic potential in an in vivo model. (PMID:18978946)
• Expression of ICAM-1 or ICAM-2 on human pancreatic cancer cells is critically important in determining the extent to which these cells are sensitive to killing by human gammadelta-T cells. (PMID:19175829)
• Data show that The cell surface expression levels of (ICAM)-2 and -3 on the apoptotic cells were markedly lower, while those of calnexin, calreticulin, and (LAMP)-1 and -2 were significantly higher compared to non-apoptotic cells. (PMID:19524015)
• Immune surveillance occurs during the early intraepithelial stages of human pancreatic carcinogenesis and is mediated by expression of CXCL17 and ICAM2. (PMID:20955708)
• These findings suggested that the downregulated miR-125b expression was associated with proliferation and radioresistance mechanisms, probably through ICAM2 signalling. (PMID:23591197)
• Reduced glycosylation of ICAM-2 significantly attenuated, but did not abolish, its ability to suppress metastatic properties of neuroblastoma cells. (PMID:23714211)
• ICAM-2 was significantly more pronounced in plasma cell mastitis than in nonpathologic breast tissue. However, no significant differences in ICAM-2 immunoreactivity were detected between ductal epithelium of PCM and non-PCM. (PMID:24457076)
• with larger patient groups and preferably detailed histopathological and clinical evaluations, are needed to explain the severity of ICAM-1, ICAM-2, and ICAM-3 molecules in Barrett’s esophagus (PMID:24474251)
• Results indicate that the interaction of ICAM-2 with alpha-actinin is critical to conferring an ICAM-2-mediated non-metastatic phenotype in neuroblastoma cells. (PMID:24704826)
• ICAM-1 and ICAM-2 are involved in each step of neutrophil extravasation, and have redundant but also distinct functions. Analysis of the role of endothelial ICAM-1 requires simultaneous consideration of ICAM-2. (PMID:25427141)
• Soluble ICAM2 was higher in ADHD patients than in controls. (PMID:26377944)
• Both ICAM-2 and ICAM-1 levels in plasma were markedly increased in Ankylosing Spondylitis Chinese patients compared to controls. (PMID:26641849)
• ICAM2 induction by p53 has a key role in inhibiting cancer cell migration and invasion.ICAM2 acts at least in part through the suppression of the MEK-ERK signaling pathway. (PMID:27556181)
• INDEED also identified some candidates previously reported to be relevant to HCC, such as intercellular adhesion molecule 2 (ICAM2) and c4b-binding protein alpha chain (C4BPA), which were missed by both Differential expression and differential network analyses (PMID:27592383)
• Lewis-antigen-containing ICAM-2/3 on Jurkat leukemia cells interact with DC-SIGN to regulate DC functions. (PMID:29671117)
• ICAM-1 and ICAM-2 Are Differentially Expressed and Up-Regulated on Inflamed Pulmonary Epithelium, but Neither ICAM-2 nor LFA-1: ICAM-1 Are Required for Neutrophil Migration Into the Airways In Vivo. (PMID:34484188)
• Intercellular adhesion molecule 2 as a novel prospective tumor suppressor induced by ERG promotes ubiquitination-mediated radixin degradation to inhibit gastric cancer tumorigenicity and metastasis. (PMID:37759298)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Icam2	ENSMUSG00000001029
rattus_norvegicus	Icam2	ENSRNOG00000025143

Paralogs (4): ICAM3 (ENSG00000076662), ICAM1 (ENSG00000090339), ICAM4 (ENSG00000105371), ICAM5 (ENSG00000105376)

Protein

Protein identifiers

Intercellular adhesion molecule 2 — P13598 (reviewed: P13598)

All UniProt accessions (8): P13598, J3KSR9, J3QKR4, J3QQR8, J3QQX6, J3QRQ1, J3QRT5, Q6FHE2

UniProt curated annotations — full annotation on UniProt →

Function. Cell adhesion molecule that functions as a receptor ligand of the signaling receptor ITGAL:ITGB2/LFA-1 (lymphocyte-function associated (LFA) molecule 1) ensuring leukocyte cell-cell adhesion on resting cells. Also endothelial blood vessels receptor ligand of dendritic cell (DC) CD209 signaling receptor that mediates triggering transendothelial migration of DC presursors from blood into peripheral tissues and, subsequently, into lymphoid tissues. Mediates adhesive interactions important for antigen presentation, lymphocyte recirculation, and other cellular interactions important for immune response and surveillance.

Subunit / interactions. Interacts with RDX, EZR and MSN.

Subcellular location. Cell membrane. Cell projection. Microvillus.

Tissue specificity. Constitutively expressed on leukocytes and endothelium. Expressed on resting lymphocytes and monocytes, but not in neutrophils. Abundantly expressed on endothelial vascular cells as well as lymphatic vessels in tonsils.

Induction. No induction by inflammatory mediators.

Similarity. Belongs to the immunoglobulin superfamily. ICAM family.

RefSeq proteins (5): NP_000864, NP_001093256, NP_001093257, NP_001093258, NP_001093259* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003987	ICAM_VCAM_N	Domain
IPR003988	ICAM	Domain
IPR013768	ICAM_N	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR047012	ICAM_VCAM	Family

Pfam: PF03921

UniProt features (39 total): strand 15, glycosylation site 6, disulfide bond 3, sequence variant 3, helix 3, topological domain 2, domain 2, signal peptide 1, chain 1, sequence conflict 1, transmembrane region 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1ZXQ	X-RAY DIFFRACTION	2.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P13598-F1	87.28	0.72

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 48–91, 52–95, 134–190

Glycosylation sites (6): 105, 153, 176, 187, 47, 82

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-216083	Integrin cell surface interactions
R-HSA-5621575	CD209 (DC-SIGN) signaling

MSigDB gene sets: 271 (showing top): TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP, WALLACE_PROSTATE_CANCER_RACE_UP, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_DENDRITIC_CELL_MIGRATION, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GOBP_CELL_CELL_ADHESION, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_LEUKOCYTE_MIGRATION, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP, ROZANOV_MMP14_TARGETS_UP, HESS_TARGETS_OF_HOXA9_AND_MEIS1_UP, SCHLOSSER_SERUM_RESPONSE_DN, DOUGLAS_BMI1_TARGETS_DN

GO Biological Process (5): cell adhesion (GO:0007155), leukocyte cell-cell adhesion (GO:0007159), cell adhesion mediated by integrin (GO:0033627), dendritic cell migration (GO:0036336), cell-cell adhesion (GO:0098609)

GO Molecular Function (2): integrin binding (GO:0005178), receptor ligand activity (GO:0048018)

GO Cellular Component (7): uropod (GO:0001931), plasma membrane (GO:0005886), microvillus (GO:0005902), membrane (GO:0016020), cleavage furrow (GO:0032154), cell projection (GO:0042995), cell periphery (GO:0071944)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Adaptive Immune System	1
Extracellular matrix organization	1
C-type lectin receptors (CLRs)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cell adhesion	2
signaling receptor binding	2
cellular process	1
cell-cell adhesion	1
mononuclear cell migration	1
protein-containing complex binding	1
cell adhesion molecule binding	1
signal transduction	1
signaling receptor activator activity	1
cell trailing edge	1
plasma membrane bounded cell projection	1
membrane	1
cell periphery	1
actin filament bundle	1
actin-based cell projection	1
cell division site	1
plasma membrane region	1

Protein interactions and networks

STRING

1554 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ICAM2	ITGB2	P05107	995
ICAM2	ITGAL	P20701	994
ICAM2	CD209	Q9NNX6	991
ICAM2	RDX	P35241	985
ICAM2	ITGAM	P11215	968
ICAM2	EZR	P15311	963
ICAM2	ICAM1	P05362	917
ICAM2	VCAM1	P19320	879
ICAM2	F11R	Q9Y624	875
ICAM2	MSN	P26038	850
ICAM2	CD44	P16070	842
ICAM2	PECAM1	P16284	802
ICAM2	SELPLG	Q14242	760
ICAM2	SELE	P16111	755
ICAM2	ICAM4	Q14773	740

IntAct

13 interactions, top by confidence:

A	B	Type	Score
vpu	SCAMP3	psi-mi:“MI:0914”(association)	0.460
ICAM2	F2RL1	psi-mi:“MI:0915”(physical association)	0.370
ICAM2	ATP13A2	psi-mi:“MI:0915”(physical association)	0.370
ICAM2	NRP1	psi-mi:“MI:0914”(association)	0.350
	NPC1	psi-mi:“MI:0914”(association)	0.350
ICAM2	RTN2	psi-mi:“MI:0914”(association)	0.350
RSU1	ICAM2	psi-mi:“MI:0914”(association)	0.350
ICAM2	RAB29	psi-mi:“MI:0914”(association)	0.350
ICAM2	asd	psi-mi:“MI:0915”(physical association)	0.000
ICAM2		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (73): YIF1B (Affinity Capture-MS), LRFN1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), RTN2 (Affinity Capture-MS), HBD (Affinity Capture-MS), LGALS1 (Affinity Capture-MS), ARL6IP5 (Affinity Capture-MS), MAD2L2 (Affinity Capture-MS), NRP1 (Affinity Capture-MS), DAGLB (Affinity Capture-MS), BSCL2 (Affinity Capture-MS), RAB18 (Affinity Capture-MS), TNFSF9 (Affinity Capture-MS), ARL6IP5 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0B4J1G0, A0A0G2KBC9, A3RFZ7, B6A8R8, E2RP87, G1T7E7, G1TR84, H0VDZ8, M3XWH1, O75015, P08101, P08508, P08637, P0DTI4, P12314, P12318, P12319, P12371, P13597, P13598, P20489, P26151, P27645, P31995, P35330, P50283, P51866, P79107, P82957, Q00238, Q08481, Q09TM2, Q09TM4, Q14952, Q28942, Q3B8P2, Q3SWT0, Q5NKV1, Q5NKV2, Q60513

Diamond homologs: P05362, P13597, P13598, P32942, P33729, P35330, Q00238, Q14773, Q28125, Q28730, Q28806, Q5NKT8, Q5NKU6, Q5NKV1, Q5NKV2, Q5NKV4, Q5NKV6, Q5NKV9, Q60625, Q95132, Q9UMF0, A2ASS6, P13688, Q00888, Q00889, Q13046, Q1WIM1, Q4VA61, Q86VR7, Q8NFZ8, Q8R464, Q8TD84, Q9ERM2, D3ZB51, O00533, O15146, Q26474, Q61006, Q62838, Q8BQC3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ERG	“up-regulates quantity by expression”	ICAM2	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

549 predictions. Top by Δscore:

Variant	Effect	Δscore
17:64002926:C:CC	acceptor_gain	1.0000
17:64003961:GGCT:G	acceptor_gain	1.0000
17:64003962:GCT:G	acceptor_gain	1.0000
17:64003963:CT:C	acceptor_gain	1.0000
17:64003963:CTC:C	acceptor_gain	1.0000
17:64003964:TCT:T	acceptor_gain	1.0000
17:64003964:TCTGC:T	acceptor_loss	1.0000
17:64003965:C:CC	acceptor_gain	1.0000
17:64003965:CTGC:C	acceptor_loss	1.0000
17:64005105:A:AC	donor_gain	1.0000
17:64005106:C:CC	donor_gain	1.0000
17:64006626:CTTA:C	donor_loss	1.0000
17:64006627:TTA:T	donor_loss	1.0000
17:64006628:TAC:T	donor_loss	1.0000
17:64006629:A:T	donor_loss	1.0000
17:64002924:CT:C	acceptor_gain	0.9900
17:64003691:C:CT	donor_gain	0.9900
17:64003692:C:CT	donor_gain	0.9900
17:64003960:AGGCT:A	acceptor_gain	0.9900
17:64003965:C:A	acceptor_gain	0.9900
17:64005106:CGGTA:C	donor_gain	0.9900
17:64005111:CACG:C	donor_gain	0.9900
17:64005216:AG:A	donor_gain	0.9900
17:64005241:T:C	donor_gain	0.9900
17:64005374:C:CC	acceptor_gain	0.9900
17:64006629:A:AC	donor_gain	0.9900
17:64006630:C:CC	donor_gain	0.9900
17:64002922:GGCT:G	acceptor_gain	0.9800
17:64002925:TC:T	acceptor_loss	0.9800
17:64002926:CT:C	acceptor_loss	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000017587 (17:64005960 G>A,T), RS1000026800 (17:64009969 C>T), RS1000095743 (17:64016465 G>T), RS1000238122 (17:64018563 G>A,T), RS1000368761 (17:64022104 C>G,T), RS1000700904 (17:64020678 G>A,C), RS1000904637 (17:64004537 A>G), RS1000949632 (17:64004251 C>T), RS1001348360 (17:64009076 C>A,T), RS1001589412 (17:64020999 A>T), RS1001750526 (17:64008522 G>T), RS1001926629 (17:64019673 G>A), RS1002022525 (17:64003310 GT>G), RS1002153626 (17:64014749 G>A), RS1002376548 (17:64019367 G>T)

Disease associations

OMIM: gene MIM:146630 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression, decreases expression	3
Tobacco Smoke Pollution	decreases expression, increases expression	3
Cadmium Chloride	decreases expression, increases expression	2
propionaldehyde	increases expression	1
bisphenol A	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
sulindac sulfide	increases expression	1
benzo(e)pyrene	increases methylation	1
vanadyl sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
entinostat	decreases expression	1
(+)-JQ1 compound	decreases expression, decreases reaction, increases expression	1
GSK1210151A	decreases reaction, increases expression, decreases expression	1
2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Decitabine	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation, decreases methylation	1
Cisplatin	increases expression	1
Diazinon	increases methylation	1
Colforsin	decreases reaction, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.